Kara Schenk is an Oncology physician. OpenAlex indexes 11 publications with 267 citations (h-index 8).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Industry payments
25 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PfizerProgram year202525 paymentsResearch$222,275openpaymentsdata.cms.gov ↗
- BioNTech SEProgram year20254 paymentsResearch$22,767openpaymentsdata.cms.gov ↗
- Stemline Therapeutics Inc.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
52.6%Aromatase Inhibitor35.9%Anastrozole72%Letrozole28%Part D≥29 patientsKinase inhibitor11.1%Verzenio59%Ibrance41%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
10.8%Corticosteroid6.5%Prednisone100%Part D≥11 patientsSerotonin-3 Receptor Antagonist4.2%Ondansetron Odt100%Part D≥11 patientsNervous system
10.5%Phenothiazine10.5%Prochlorperazine Maleate100%Part D≥23 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers
Journal of Clinical Oncology
2024 - 695 Phase 2 study of nivolumab and ipilimumab in combination with sirolimus and prednisone in kidney transplant recipients with selected unresectable or metastatic cutaneous cancers
Regular and Young Investigator Award Abstracts
2024 - Trainee-led quality improvement (QI) project examining PCP prophylaxis in patients on chronic, high-dose corticosteroids.
Journal of Clinical Oncology
2024 - Immune microenvironment of basal cell carcinoma and tumor regression following combined PD-1/LAG-3 blockade
Journal for ImmunoTherapy of Cancer
2023
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Beth Karlan, MD
University of California, Los Angeles
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”